Daily Scoop🍨: Genprex (GNPX) Earnings Strong Buy 🙏💪🔥

$Genprex, Inc.(GNPX)$

Genprex Inc GNPX.OQ reported a quarterly adjusted loss of $1.23 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The mean expectation of two analysts for the quarter was for a loss of $1.93 per share. Wall Street expected results to range from $-2.73 to $-1.13 per share.

Reported revenue was expected !

Genprex Inc's reported EPS for the quarter was a loss of $1.23.

The company reported a quarterly loss of $4.32 million.

Genprex Inc shares had risen by 477.8% this quarter and lost 77.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Genprex Inc is 8.75

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

14

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":371170212446376,"tweetId":"371170212446376","gmtCreate":1731635799599,"gmtModify":1731652518758,"author":{"id":4088639346266630,"idStr":"4088639346266630","authorId":4088639346266630,"authorIdStr":"4088639346266630","name":"daz888888888","avatar":"https://community-static.tradeup.com/news/8bbe8cd95504dc1e0dd3af78504d3f7e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.18%","individualDisplayEnabled":0},"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.15","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":2261,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[],"coverImages":[],"title":"Daily Scoop🍨: Genprex (GNPX) Earnings Strong Buy 🙏💪🔥","html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/GNPX\">$Genprex, Inc.(GNPX)$</a>&nbsp;</p>\n<p>Genprex Inc GNPX.OQ reported a quarterly adjusted loss of $1.23 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The mean expectation of two analysts for the quarter was for a loss of $1.93 per share. Wall Street expected results to range from $-2.73 to $-1.13 per share.</p>\n<p>Reported revenue was expected !</p>\n<p><br></p>\n<p>Genprex Inc's reported EPS for the quarter was a loss of $1.23.</p>\n<p>The company reported a quarterly loss of $4.32 million.</p>\n<p>Genprex Inc shares had risen by 477.8% this quarter and lost 77.3% so far this year.</p>\n<p>FORECAST CHANGES</p>\n<p>The mean earnings estimate of analysts was unchanged in the last three months.</p>\n<p>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p>\n<p>RECOMMENDATIONS</p>\n<p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"</p>\n<p>The average consensus recommendation for the biotechnology &amp; medical research peer group is also \"strong buy\"</p>\n<p>Wall Street's median 12-month price target for Genprex Inc is 8.75</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/GNPX\">$Genprex, Inc.(GNPX)$</a>&nbsp;</p>\n<p>Genprex Inc GNPX.OQ reported a quarterly adjusted loss of $1.23 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The mean expectation of two analysts for the quarter was for a loss of $1.93 per share. Wall Street expected results to range from $-2.73 to $-1.13 per share.</p>\n<p>Reported revenue was expected !</p>\n<p><br></p>\n<p>Genprex Inc's reported EPS for the quarter was a loss of $1.23.</p>\n<p>The company reported a quarterly loss of $4.32 million.</p>\n<p>Genprex Inc shares had risen by 477.8% this quarter and lost 77.3% so far this year.</p>\n<p>FORECAST CHANGES</p>\n<p>The mean earnings estimate of analysts was unchanged in the last three months.</p>\n<p>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p>\n<p>RECOMMENDATIONS</p>\n<p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"</p>\n<p>The average consensus recommendation for the biotechnology &amp; medical research peer group is also \"strong buy\"</p>\n<p>Wall Street's median 12-month price target for Genprex Inc is 8.75</p></body></html>","text":"$Genprex, Inc.(GNPX)$ Genprex Inc GNPX.OQ reported a quarterly adjusted loss of $1.23 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The mean expectation of two analysts for the quarter was for a loss of $1.93 per share. Wall Street expected results to range from $-2.73 to $-1.13 per share. Reported revenue was expected ! Genprex Inc's reported EPS for the quarter was a loss of $1.23. The company reported a quarterly loss of $4.32 million. Genprex Inc shares had risen by 477.8% this quarter and lost 77.3% so far this year. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the biotechnology & medical research peer group is also \"strong buy\" Wall Street's median 12-month price target for Genprex Inc is 8.75","highlighted":1,"essential":1,"paper":2,"likeSize":14,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/371170212446376","repostId":0,"isVote":1,"tweetType":1,"viewCount":137,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["GNPX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":971,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/371170212446376"}